Skip to main navigation Skip to search Skip to main content

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

  • Tanya Dorff
  • , Lisa G. Horvath
  • , Karen Autio
  • , Alice Bernard-Tessier
  • , Matthew B. Rettig
  • , Jean-Pascal Machiels
  • , Mehmet A. Bilen
  • , Martijn P. Lolkema
  • , Nabil Adra
  • , Sylvie Rottey
  • , Richard Greil (Co-author)
  • , Nobuaki Matsubara
  • , Daniel S. W. Tan
  • , Alvin Wong
  • , Hiroji Uemura
  • , Charlotte Lemech
  • , Johannes Meran
  • , Youfei Yu
  • , Mukul Minocha
  • , Mason Mccomb
    • Hweixian Leong Penny, Vinita Gupta, Xuguang Hu, Gabor Jurida, Hosein Kouros-Mehr, Margit M. Janat-Amsbury, Tobias Eggert, Ben Tran
  • City of Hope
  • Chris O'Brien Lifehouse
  • Memorial Sloan Kettering Cancer Center
  • UNICANCER
  • US Department of Veterans Affairs
  • Universite Catholique Louvain
  • Erasmus University Medical Center Rotterdam
  • Amgen
  • Indiana University System
  • Salzburg Canc Res Inst CCCIT
  • National Cancer Centre Singapore (NCCS)
  • National University of Singapore
  • Yokohama City University
  • University of New South Wales Sydney

Research output: Contribution to journal › Original Article › peer-review

55 Citations (Web of Science)

Fingerprint

Dive into the research topics of 'A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science